Daly, O.; Mahiny, A.J.; Majeski, S.; McClintock, K.; Reichert, J.; Boros, G.; Szabó, G.T.; Reinholz, J.; Schreiner, P.; Reid, S.;
et al. ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model. Biomedicines 2023, 11, 1735.
https://doi.org/10.3390/biomedicines11061735
AMA Style
Daly O, Mahiny AJ, Majeski S, McClintock K, Reichert J, Boros G, Szabó GT, Reinholz J, Schreiner P, Reid S,
et al. ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model. Biomedicines. 2023; 11(6):1735.
https://doi.org/10.3390/biomedicines11061735
Chicago/Turabian Style
Daly, Owen, Azita Josefine Mahiny, Sara Majeski, Kevin McClintock, Julia Reichert, Gábor Boros, Gábor Tamás Szabó, Jonas Reinholz, Petra Schreiner, Steve Reid,
and et al. 2023. "ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model" Biomedicines 11, no. 6: 1735.
https://doi.org/10.3390/biomedicines11061735
APA Style
Daly, O., Mahiny, A. J., Majeski, S., McClintock, K., Reichert, J., Boros, G., Szabó, G. T., Reinholz, J., Schreiner, P., Reid, S., Lam, K., Lepper, M., Adler, M., Meffen, T., Heyes, J., Karikó, K., Lutwyche, P., & Vlatkovic, I.
(2023). ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model. Biomedicines, 11(6), 1735.
https://doi.org/10.3390/biomedicines11061735
